Format

Send to

Choose Destination
Pediatrics. 2013 Jan;131(1):e336-41. doi: 10.1542/peds.2012-0376. Epub 2012 Dec 24.

Complete remission following decitabine/dendritic cell vaccine for relapsed neuroblastoma.

Author information

1
Division of Hematology/Oncology, Department of Pediatrics, Stem Cell Transplantation Program, Penn State Children’s Hospital, Hershey, Pennsylvania 17033, USA.

Erratum in

  • Pediatrics. 2013 Jul;132(1):173.

Abstract

Patients with relapsed stage 4 neuroblastoma have an extremely poor long-term prognosis, making the investigation of new agents of interest. We report the outcome of the first patient treated in a phase 1 study for relapsed neuroblastoma, using the chemotherapy agent decitabine to upregulate cancer testis antigen expression, followed by a dendritic cell vaccine targeting the cancer testis antigens MAGE-A1, MAGE-A3, and NY-ESO-1. Our patient had persistent tumor in his bone marrow after completion of standard therapy for neuroblastoma, including multiagent chemotherapy, tumor resection, stem cell transplantation, radiation therapy, and anti-GD2 monoclonal antibodies. His marrow disease persisted despite chemotherapy, which was given while the vaccine was being produced. After 3 cycles of decitabine and vaccine, this patient achieved a complete remission and is now 1 year from his last treatment, with no evidence of tumor in his bone marrow or other sites. This patient was noted to have an increase in MAGE-A3-specific T cells. This is the first report combining demethylating chemotherapy to enhance tumor antigen expression followed by a cancer antigen vaccine.

PMID:
23266925
DOI:
10.1542/peds.2012-0376
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center